Vestibular Migraine Clinical Trials 2023

Vestibular Migraine Clinical Trials 2023

Vestibular Migraine research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in vestibular migraine clinical trials today.

Trials for Dizziness Patients

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to vestibular migraine

What are the top hospitals conducting vestibular migraine research?

When it comes to cutting-edge clinical trials focused on vestibular migraine, several hospitals are making significant strides in research and treatment. Otolith Labs, located in Washington, leads the way with two active trials dedicated to this debilitating condition. Although relatively new to the field, having recorded their first trial in 2021, their commitment to finding innovative solutions is evident. Moving down south to Pasadena, California, Kaiser Permanente Southern California joins the ranks with one ongoing vestibular migraine trial and a promising track record of being at the forefront of medical advancements; they initiated their first study in 2022. In Amqui, Canada, Centre Hospitalier d'Amqui has also made substantial contributions through its active vestibular migraine trial and marks a milestone as it delves into this specific area for the first time this year.

Similarly joining forces are Centre Hospitalier de Matane and Centre Hospitalier de Montmagny—both situated in different regions of Canada—embracing groundbreaking research by conducting active investigations into vestibular migraines as well. These hospitals each have one ongoing clinical trial under their belts while demonstrating an unwavering dedication that commenced just recently in 2022.

The pursuit of understanding and combating vestibular migraines requires collaboration from diverse institutions across countries. The efforts put forth by these leading hospitals not only elevate our knowledge about this complex condition but also pave the way for much-needed breakthroughs that will improve the lives of those affected worldwide

Which are the best cities for vestibular migraine clinical trials?

In the realm of vestibular migraine clinical trials, a few cities have emerged as key players in advancing research and treatment. Washington, D.C., boasts 4 active trials investigating Ebselen, the efficacy of Otoband versus Sham A, and other interventions. Likewise, Los Angeles, California has 4 ongoing studies exploring Montelukast and Ebselen among other potential therapies. San Francisco showcases 3 active trials focusing on Galcanezumab Prefilled Syringe, Ebselen, and more. Lastly, San Diego and New york each house 2 active trials centered on evaluating the effectiveness of Ebselen along with other experimental treatments. These cities offer valuable opportunities for individuals affected by vestibular migraines to participate in cutting-edge clinical trials that may pave the way for improved management and relief of symptoms.

Which are the top treatments for vestibular migraine being explored in clinical trials?

In the realm of vestibular migraine treatment, two emerging options are capturing attention in clinical trials. The Frenzel Lens, introduced just recently in 2022, is currently being explored in one active trial dedicated to vestibular migraines. Montelukast is another contender gaining traction with its inclusion in one ongoing clinical trial since its listing last year in 2021. As researchers delve deeper into these potential treatments, they offer hope for those living with the challenges of vestibular migraines and pave the way for better management strategies moving forward.

What are the most recent clinical trials for vestibular migraine?

Exciting advancements are underway in the field of vestibular migraine research, offering renewed hope for those affected by this debilitating condition. One notable clinical trial focuses on the efficacy of Ebselen—a promising drug candidate—in treating vestibular migraines. Another study explores the potential benefits of Montelukast, while a separate trial investigates Lamotrigine and Bupropion as potential treatment options. Moreover, Galcanezumab Prefilled Syringe is being evaluated for its effectiveness in managing symptoms associated with vestibular migraines. These trials signify significant progress towards improving the lives of individuals grappling with this challenging disorder.

What vestibular migraine clinical trials were recently completed?

In recent times, several clinical trials investigating vestibular migraine have reached completion, shedding light on potential advancements in its treatment. Notably, a trial examining the effectiveness of Uproleselan was concluded by Washington University School of Medicine in October 2021. Furthermore, the National Cancer Institute successfully completed a trial involving mRNA-1273 for this condition in September 2021. Lastly, AgenTus Therapeutics wrapped up their agenT-797 study related to vestibular migraine in January 2021. These significant milestones signify progress and offer hope for individuals grappling with vestibular migraine as researchers continue to strive towards improved treatments.